Co-Diagnostics, Inc. Proceeds from Sale and Maturity of Marketable Securities
Co-Diagnostics, Inc. (CODX) reported Proceeds from Sale and Maturity of Marketable Securities of $33.67 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-08-13
- Co-Diagnostics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was -$94.89K, a 100.69% decline year-over-year.
- Co-Diagnostics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $2.25M, a 87.62% decline year-over-year.
- Co-Diagnostics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-06-30 was $17.62M, a 86.34% increase year-over-year.
- Co-Diagnostics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-03-31 was $13.89M, a 20.07% decline year-over-year.
- Co-Diagnostics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2025 was $33.67M, a 42.71% decline from fiscal 2024.
- Co-Diagnostics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2024 was $58.77M, a 53.82% decline from fiscal 2023.
- Co-Diagnostics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2023 was $127.25M, a 1030.60% increase from fiscal 2022.
- Co-Diagnostics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2022 was $11.26M, a 265.41% increase from fiscal 2021.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$94.89K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $2.16M derived: sum of 2 quarters · filed 2026-03-31 | $19.77M derived: sum of 3 quarters · filed 2026-08-13 | $33.67M 10-K · filed 2026-03-31 |
| 2025-09-30 | $2.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $19.87M derived: sum of 2 quarters · filed 2026-08-13 | $33.76M 10-Q · filed 2025-11-13 | $47.50M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $17.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $31.51M 10-Q · filed 2026-08-13 | $45.24M derived: sum of 3 quarters · filed 2026-08-13 | $63.44M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $13.89M 10-Q · filed 2026-05-14 | $27.63M derived: sum of 2 quarters · filed 2026-05-14 | $45.82M derived: sum of 3 quarters · filed 2026-05-14 | $55.28M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $13.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $31.93M derived: sum of 2 quarters · filed 2026-03-31 | $41.38M derived: sum of 3 quarters · filed 2026-03-31 | $58.77M 10-K · filed 2026-03-31 |
| 2024-09-30 | $18.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $27.65M derived: sum of 2 quarters · filed 2025-11-13 | $45.03M 10-Q · filed 2025-11-13 | $82.00M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $9.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $26.84M 10-Q · filed 2025-08-14 | $63.81M derived: sum of 3 quarters · filed 2025-08-14 | $84.69M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $17.38M 10-Q · filed 2025-05-08 | $54.36M derived: sum of 2 quarters · filed 2025-05-08 | $75.24M derived: sum of 3 quarters · filed 2025-05-08 | $114.09M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $36.97M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $57.86M derived: sum of 2 quarters · filed 2025-03-27 | $96.71M derived: sum of 3 quarters · filed 2025-03-27 | $127.25M 10-K · filed 2025-03-27 |
| 2023-09-30 | $20.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $59.74M derived: sum of 2 quarters · filed 2024-11-07 | $90.28M 10-Q · filed 2024-11-07 | $95.31M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $38.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $69.39M 10-Q · filed 2024-08-08 | $74.43M derived: sum of 3 quarters · filed 2024-08-08 | $79.39M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $30.54M 10-Q · filed 2024-05-09 | $35.57M derived: sum of 2 quarters · filed 2024-05-09 | $40.54M derived: sum of 3 quarters · filed 2024-05-09 | $40.54M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $5.03M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $10.00M derived: sum of 2 quarters · filed 2024-03-14 | $10.00M derived: sum of 3 quarters · filed 2024-03-14 | $11.26M 10-K · filed 2024-03-14 |
| 2022-09-30 | $4.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $4.97M derived: sum of 2 quarters · filed 2023-11-09 | $6.22M 10-Q · filed 2023-11-09 | $6.22M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $1.26M 10-Q · filed 2023-08-10 | $1.25M derived: sum of 3 quarters · filed 2023-08-10 | $2.11M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $1.26M 10-Q · filed 2023-05-11 | $1.25M derived: sum of 2 quarters · filed 2023-05-11 | $2.11M derived: sum of 3 quarters · filed 2023-05-11 | $2.30M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$3.98K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $854.41K derived: sum of 2 quarters · filed 2023-03-16 | $1.05M derived: sum of 3 quarters · filed 2023-03-16 | $3.08M 10-K · filed 2023-03-16 |
| 2021-09-30 | $858.39K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.05M derived: sum of 2 quarters · filed 2022-11-10 | $3.08M 10-Q · filed 2022-11-10 | $4.80M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $192.97K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $2.23M 10-Q · filed 2022-08-11 | $3.94M derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | $2.03M 10-Q · filed 2022-05-12 | $3.75M derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $4.97M 10-K · filed 2022-03-24 | ||
| 2020-09-30 | $3.26M 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| enVVeno Medical Corp (NVNO) | United States | $0.006B | -0.48 |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| ALLURION TECHNOLOGIES, INC. (ALUR) | United States | $0.010B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Picard Medical, Inc. (PMI) | United States | $0.011B | -0.01 |